GlassScriptPhysician profile
Christopher R Gordon
NPI 1922232867
$1,386.65
in general payments reported to CMS, 2019-2025
13 companies · $296 in 2025
The $296 reported for 2025 was more than what 75% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $127 · 2021: $276 · 2022: $210 · 2023: $245 · 2024: $233 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $773.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $442.21 | 2022-2025 | Prolastin-C Liquid, Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $233.72 | 2021-2024 | Hyqvia, Cuvitru |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.99 | 2020-2021 | |
| Kaleo, INC. | $150.45 | 2020-2023 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $110.45 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $85.15 | 2021-2022 | |
| Trice Medical, INC. | $76.31 | 2025 | |
| Glaxosmithkline, LLC. | $43.69 | 2020-2022 | |
| Ars Pharmaceuticals Operations, INC. | $21.17 | 2025 | Neffy |
| Organon LLC | $19.20 | 2025 | |
| Genentech USA, INC. | $17.63 | 2023 | Xolair |
| Genzyme Corporation | $17.00 | 2025 | |
| Merck Sharp & Dohme LLC | $15.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.